16 reports of this reaction
2.8% of all CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE reports
#6 most reported adverse reaction
DRY SKIN is the #6 most commonly reported adverse reaction for CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, manufactured by Bausch Health US, LLC. There are 16 FDA adverse event reports linking CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE to DRY SKIN. This represents approximately 2.8% of all 579 adverse event reports for this drug.
Patients taking CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE who experience dry skin should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRY SKIN is a less commonly reported adverse event for CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, but still significant enough to appear in the safety profile.
In addition to dry skin, the following adverse reactions have been reported for CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE:
The following drugs have also been linked to dry skin in FDA adverse event reports:
DRY SKIN has been reported as an adverse event in 16 FDA reports for CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRY SKIN accounts for approximately 2.8% of all adverse event reports for CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, making it a notable side effect.
If you experience dry skin while taking CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.